Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat for Treatment of C. difficile Infection (CDI)

Nov 5, 2020

Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Jul 23, 2020

Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection

Jan 15, 2020

Acurx Pharmaceuticals to Present at Two Prominent International Healthcare Conferences

Nov 4, 2019

Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences

Oct 3, 2019

Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI

Aug 28, 2019

Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI

Feb 27, 2019

Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection

Jan 16, 2019

Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections

Oct 4, 2018

FDA Grants QIDP Designation to Acurx’s Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection

Jun 20, 2018